» Articles » PMID: 25234961

Hidradenitis Suppurativa in Children and Adolescents: a Review of Treatment Options

Overview
Journal Paediatr Drugs
Specialties Pediatrics
Pharmacology
Date 2014 Sep 20
PMID 25234961
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Hidradenitis suppurativa (HS) is a burdensome disease and has the potential to affect the life course of patients. It is a rare disease in children, and the recorded literature is correspondingly scarce. This article reviews the therapeutic options for HS in children and adolescents, and highlights particular differences or challenges with treating patients in this age group compared with adults. The work-up of paediatric patients with HS should include considerations of possible endocrine co-morbidities and obesity. Medical therapy of lesions may include topical clindamycin. Systemic therapy may include analgesics, clindamycin and rifampicin, finasteride, corticosteroids or tumour necrosis factor alpha (TNFα) blockers. Superinfections should be appropriately treated. Scarring lesions generally require surgery.

Citing Articles

Hidradenitis suppurativa; classification, remedies, etiology, and comorbidities; a narrative review.

Mohammadi S, Gholami A, Hejrati L, Rohani M, Rafiei-Sefiddashti R, Hejrati A J Family Med Prim Care. 2022; 10(11):4009-4016.

PMID: 35136760 PMC: 8797099. DOI: 10.4103/jfmpc.jfmpc_795_21.


Multidisciplinary Management of Adolescents with Hidradenitis Suppurativa - Series of Cases and Literature Review.

Tarca E, Cojocaru E, Caba B, Luca A, Rosu S, Tarca V J Multidiscip Healthc. 2021; 14:2205-2216.

PMID: 34429610 PMC: 8378912. DOI: 10.2147/JMDH.S324325.


Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patients.

Riis P, Saunte D, Sigsgaard V, Villani A, Guillem P, Pascual J Arch Dermatol Res. 2020; 312(10):715-724.

PMID: 32166376 DOI: 10.1007/s00403-020-02053-6.


Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology.

Magalhaes R, Rivitti-Machado M, Duarte G, Souto R, Nunes D, Chaves M An Bras Dermatol. 2019; 94(2 Suppl 1):7-19.

PMID: 31166401 PMC: 6544037. DOI: 10.1590/abd1806-4841.20198607.


North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C J Am Acad Dermatol. 2019; 81(1):91-101.

PMID: 30872149 PMC: 9131892. DOI: 10.1016/j.jaad.2019.02.068.


References
1.
Brecher A, Orlow S . Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol. 2003; 49(2):171-82; quiz 183-6. DOI: 10.1067/s0190-9622(03)01564-0. View

2.
Grant A, Gonzalez T, Montgomery M, Cardenas V, Kerdel F . Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010; 62(2):205-17. DOI: 10.1016/j.jaad.2009.06.050. View

3.
Soria A, Canoui-Poitrine F, Wolkenstein P, Poli F, Gabison G, Pouget F . Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients' outcome assessment. Dermatology. 2008; 218(2):134-5. DOI: 10.1159/000182261. View

4.
Feito-Rodriguez M, Sendagorta-Cudos E, Herranz-Pinto P, de Lucas-Laguna R . Prepubertal hidradenitis suppurativa successfully treated with botulinum toxin A. Dermatol Surg. 2009; 35(8):1300-2. DOI: 10.1111/j.1524-4725.2009.01231.x. View

5.
Alharbi Z, Kauczok J, Pallua N . A review of wide surgical excision of hidradenitis suppurativa. BMC Dermatol. 2012; 12:9. PMC: 3407534. DOI: 10.1186/1471-5945-12-9. View